Related Experiment Video
Updated: May 5, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
Published on: June 25, 2013
Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂
Jessica K Norberg1, Earlphia Sells, Hui-Hua Chang
1The University of Arizona Cancer Center, Tucson, AZ 85724, USA.
Targeting the mPGES-1 enzyme is crucial for inflammation, but no selective inhibitors exist. Despite numerous patents, no mPGES-1 drugs have reached clinical trials.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Prostaglandin E2 (PGE2) pathway is implicated in inflammation-driven diseases.
- Cardiovascular risks associated with long-term COX-2 inhibitor use necessitate alternative therapeutic strategies.
- Microsomal prostaglandin E synthase-1 (mPGES-1) is a key target for modulating PGE2 production.
Purpose of the Study:
- To review patents related to mPGES-1 activity measurement.
- To analyze drugs and modulators targeting mPGES-1 and extracellular PGE2.
- To present perspectives on the current status of mPGES-1 targeting drugs.
Main Methods:
- Literature review of patent databases.
- Analysis of patents covering mPGES-1 activity assays.
- Review of patents on mPGES-1 inhibitors and PGE2 modulators.
Main Results:
- No selective inhibitors targeting mPGES-1 have been identified.
- A significant number of patents exist for mPGES-1 targeting methods and compounds.
- Despite extensive patent activity, no mPGES-1 targeting drugs have advanced to clinical trials.
Conclusions:
- The development of selective mPGES-1 inhibitors remains a challenge.
- Current patent landscape shows high interest but limited clinical translation for mPGES-1 drugs.
- Further research is needed to identify effective and safe mPGES-1 targeting therapeutics.
More Related Videos
12:50Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acute Inflammation II: Local and Systemic Effects